Role of SMAD proteins in colitis-associated cancer: from known to the unknown

被引:30
作者
Chandrasinghe, P. [1 ,2 ,3 ]
Cereser, B. [1 ]
Moorghen, M. [2 ]
Al Bakir, I. [2 ,4 ]
Tabassum, N.
Hart, A. [1 ,2 ]
Stebbing, J. [1 ]
Warusavitarne, J. [1 ,2 ]
机构
[1] Imperial Coll London, Dept Surg & Canc, London, England
[2] St Marks Hosp, Harrow, Middx, England
[3] Univ Kelaniya, Kelaniya, Sri Lanka
[4] Queen Mary Univ London, Barts Canc Inst, London, England
基金
英国医学研究理事会;
关键词
INFLAMMATORY-BOWEL-DISEASE; GROWTH-FACTOR-BETA; EMBRYONIC STEM-CELLS; ULCERATIVE-COLITIS; COLORECTAL-CANCER; COLON-CANCER; ANTISENSE OLIGONUCLEOTIDE; CROHNS-DISEASE; T-CELLS; SELF-RENEWAL;
D O I
10.1038/onc.2017.300
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Small mothers against decapentaplegic (SMAD) proteins are a family of signal transduction molecules in transforming growth factor beta (TGF beta) ligand pathways that have been found to have a key role in the pathogenesis of inflammatory bowel disease (IBD). Long standing IBD predisposes individuals to colitis-associated colorectal cancer (CAC), an entity that possess unique characteristics compared to hereditary and sporadic cancer. The ligands of the TGF beta super family along with SMADs have also been implicated in several aspects of colorectal cancer formation. SMAD proteins are shown to be involved in a number of potentially carcinogenic mechanisms such as altering gene transcription, controlling stem cell differentiation to causing epigenetic changes. Modulation of these proteins has emerged as a novel therapeutic intervention for IBD although its effect on carcinogenesis remains elusive. This account reviews available evidence linking SMAD proteins to CAC and explores the potential areas for future research in this area.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 67 条
[1]
European evidence based consensus for endoscopy in inflammatory bowel disease [J].
Annese, Vito ;
Daperno, Marco ;
Rutter, Matthew D. ;
Amiot, Aurelien ;
Bossuyt, Peter ;
East, James ;
Ferrante, Marc ;
Goetz, Martin ;
Katsanos, Konstantinos H. ;
Kiesslich, Ralf ;
Ordas, Ingrid ;
Repici, Alessandro ;
Rosa, Bruno ;
Sebastian, Shaji ;
Kucharzik, Torsten ;
Eliakim, Rami .
JOURNAL OF CROHNS & COLITIS, 2013, 7 (12) :982-1018
[2]
[Anonymous], 2002, GENE CHROMOSOME CANC, V35, P121
[3]
p53 Brings a New Twist to the Smad Signaling Network [J].
Atfi, Azeddine ;
Baron, Roland .
SCIENCE SIGNALING, 2008, 1 (26) :pe33
[4]
The APC/β-catenin pathway in ulcerative colitis-related colorectal carcinomas -: A mutational analysis [J].
Aust, DE ;
Terdiman, JP ;
Willenbucher, RF ;
Chang, CG ;
Molinaro-Clark, A ;
Baretton, GB ;
Loehrs, U ;
Waldman, FM .
CANCER, 2002, 94 (05) :1421-1427
[5]
Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease [J].
Babyatsky, MW ;
Rossiter, G ;
Podolsky, DK .
GASTROENTEROLOGY, 1996, 110 (04) :975-984
[6]
Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO
[7]
2-Z
[8]
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-β1-mediated suppression of colitis [J].
Boirivant, Monica ;
Pallone, Francesco ;
Di Giacinto, Claudia ;
Fina, Daniele ;
Monteleone, Ivan ;
Marinaro, Mariarosaria ;
Caruso, Roberta ;
Colantoni, Alfredo ;
Palmieri, Giampiero ;
Sanchez, Massimo ;
Strober, Warren ;
MacDonald, Thomas T. ;
Monteleone, Giovanni .
GASTROENTEROLOGY, 2006, 131 (06) :1786-1798
[9]
SMAD7 is a prognostic marker in patients with colorectal cancer [J].
Boulay, JL ;
Mild, G ;
Lowy, A ;
Reuter, J ;
Lagrange, M ;
Terracciano, L ;
Laffer, U ;
Herrmann, R ;
Rochlitz, C .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (04) :446-449
[10]
MUTATIONS IN THE P53 GENE - AN EARLY MARKER OF NEOPLASTIC PROGRESSION IN ULCERATIVE-COLITIS [J].
BRENTNALL, TA ;
CRISPIN, DA ;
RABINOVITCH, PS ;
HAGGITT, RC ;
RUBIN, CE ;
STEVENS, AC ;
BURMER, GC .
GASTROENTEROLOGY, 1994, 107 (02) :369-378